AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS MEMBER

这项建议的长远目标，是提高 艾滋病毒相关恶性肿瘤患者的生命和存活率， 开发创新的、发病机制驱动的治疗策略， 来深入了解这些肿瘤的生物学。为了实现这一 目标，我们的近期目标是成为临床试验成员的 艾滋病相关肿瘤联盟（RFA联盟）。这项建议 介绍了一个由四个机构及其附属机构组成的联盟， 作为临床试验的一员组成的四个机构 我们的联盟，西北大学，华盛顿大学，约翰 霍普金斯肿瘤中心和拉什医学院/伊利诺伊共济会 每个医院都有临床或基础科学专业知识， 为RFA联合会的使命做出贡献。 作为艾滋病相关肿瘤联盟的临床试验成员， 我们将在组织结构内开展活动， 由财团成立。我们将全面参与规划 以及开展联盟临床试验和研究活动。我们 将与联合体充分合作，以确保高效 沟通，遵守联邦授权的高标准 监管要求、患者登记、出版物监督， 肿瘤缓解评价以及生物统计学协调 和数据收集。参与RFA联盟临床试验 将是我们的最高优先事项，并将作为主要场所， 针对所有艾滋病相关患者的I期和II期临床试验 在我们医院评估的恶性肿瘤。

The long term objective of this proposal is to improve the quality of life and survival of patients with HIV-related malignancies through the development of innovative, pathogenesis driven therapeutic strategies and to gain insights into the biology of these tumors. To accomplish this aim, our immediate goal is to become a clinical trials member of the AIDS-Related Malignancies Consortium (RFA Consortium). This proposal presents a Consortium of four institutions and their affiliates, applying as a single clinical trials member. The four institutions which compose our Consortium, Northwestern University, Washington University, Johns Hopkins Oncology Center and Rush Medical College/Illinois Masonic Hospital, each have clinical or basic science expertise which will contribute to the mission of the RFA Consortium. As a clinical trials member of the AIDS-Related Malignancies Consortium, we will conduct our activities within the organizational structure established by the Consortium. We will participate fully in the planning and conduct of Consortium clinical trials and research activities. We will cooperate fully with the Consortium to ensure efficient communication, high standards of compliance with federally mandated regulatory requirements, patient registration, oversight of publications, evaluation of tumor response, as well as coordination of biostatistics and data collection. Participation in the RFA Consortium clinical trials will be our highest priority and will serve as the primary venue for Phase I and ll clinical trials for all patients with AIDS-related malignancies evaluated at our hospitals.